Invivyd, Inc.'s (NASDAQ:IVVD) Shift From Loss To Profit

Invivyd, Inc. (NASDAQ:IVVD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The US$92m market-cap company’s loss lessened since it announced a US$170m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$143m, as it approaches breakeven. Many investors are wondering about the rate at which Invivyd will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

According to the 3 industry analysts covering Invivyd, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$123m in 2026. Therefore, the company is expected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 52%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

We're not going to go through company-specific developments for Invivyd given that this is a high-level summary, though, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

See our latest analysis for Invivyd

One thing we’d like to point out is that Invivyd has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are key fundamentals of Invivyd which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Invivyd, take a look at Invivyd's company page on Simply Wall St. We've also compiled a list of key factors you should further research:

1. Valuation: What is Invivyd worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Invivyd is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Invivyd’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.